Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Medicare Decisions Accountability Act of 2011
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare Part-D non-interference and rebate issues; Medicare Decisions Accountability Act of 2011 (IPAB repeal) (HR 452);
Medicare Decisions Accountability Act of 2011
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare Part D Non-Interference, Rebate Issues, Medicare Decisions Accountability Act of 2011 - IPAB Repeal (HR 452)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2011 · second_quarter · Q2
Trans-Pacific Partnership Agreement; Korean Free trade Agreement; TPP IP/Market Access; ASEAN Countries Market Access/IP; IMF Policy on Greece; Veterinary medicine - domestic and international trade; Germany pricing reforms; Poland market access; Greece pricing reform; Romania cost-containment; CEE cost-containment; Anti-Counterfeiting; Turkey policy; PNTR for Russia
Medicare Part-D non-interference and rebate issues; Medicare Decisions Accountability Act of 2011 (IPAB repeal) (HR 452);
Source: Senate LDA
America's Affordable Health Choices Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Healthcare Reform (HR 4872 & HR 3590); FOB provisions (HR 3200)
America's Affordable Health Choices Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare reimbursement and coverage policies; Healthcare reform (HR 3590 & HR 4872); food safety; Patient Protection and Affordable Care Act (HR 3590); FOB provisions (HR 3200)
Patent Reform Ace (S 515); Russian data exclusitivity; Saudi Zyprexa Patent nullification; Russia DE Enactment, Manager's Amendment to S 515; Counterfeit medicines
American Middle Class Tax (AMT) Relief Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Healthcare Reform (HR 4872 & HR 3590); FOB provisions (HR 3200)
American Middle Class Tax (AMT) Relief Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare reimbursement and coverage policies; Healthcare reform (HR 3590 & HR 4872); food safety; Patient Protection and Affordable Care Act (HR 3590); FOB provisions (HR 3200)
Overseas Voting Education and Reform, Safeguarding Every American's Vote Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Financial derivatives (HR 4173)
To suspend temporarily the duty on 1-Amino-2,6-dimethylbenzene.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare reimbursement and coverage policies; Healthcare reform (HR 3590 & HR 4872); food safety; Patient Protection and Affordable Care Act (HR 3590); FOB provisions (HR 3200)
To suspend temporarily the duty on 1-Amino-2,6-dimethylbenzene.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Healthcare Reform (HR 4872 & HR 3590); FOB provisions (HR 3200)
Follow-on biologics (HR 1548, HR 1427, S 726), Patent Reform (HR 1260, S 515, S 615), China IPR, Thailand IPR, Global Intellectual Property Rights and Anti-Counterfeiting
Off-shore tax (HR 1265), Repatriation (HR 1), American Recovery and Reinvestment Act (S 1)
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Follow-on biologics (HR 1548, HR 1427, S 726), Patent Reform (HR 1260, S 515, S 615), China IPR, Thailand IPR, Global Intellectual Property Rights and Anti-Counterfeiting
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Health Care Reform, Comparative Effectiveness Research (S 1213, HR 2502, S 1259), Drug Importation, Follow-on biologics (HR 1548, HR 1427, S 726)
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Follow-on biologics (HR 1548, HR 1427, S 726), Patent Reform (HR 1260, S 515, S 615), China IPR, Thailand IPR, Global Intellectual Property Rights and Anti-Counterfeiting
Health Care Reform, Comparative Effectiveness Research (S 1213, HR 2502, S 1259), Drug Importation, Follow-on biologics (HR 1548, HR 1427, S 726)
Patent legislation; HR 1548; Follow-On Biologics; Russia IP; A;geria market access; Brazil IP; Mexico IP; Argentina IP; Chile IP; Columbia IP; Peru IP; Isreal IP; Saudi Arbia pricing and IP; Turkey pricing
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Comparative Effectiveness Research Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
"The Affordable Health Choices Act" (HR 3200, S xxx); "The America's Health Future Act" (S xxx); Waxman medicare Part-D rebate; Comparative effectiveness research (HR 2502, HR 2824); Comparative effectiveness research; Sunshine Amendments
Comparative Effectiveness Research Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Waxman Medicare part-D Non-Interference; Comparative Effectiveness Research (HR 2502, HR 2824); Medicare Commission
Comparative Effectiveness Research Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Health Care Reform, Comparative Effectiveness Research (S 1213, HR 2502, S 1259), Drug Importation, Follow-on biologics (HR 1548, HR 1427, S 726)
Doctor-Patient Relationship and Research Protection Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Waxman Medicare part-D Non-Interference; Comparative Effectiveness Research (HR 2502, HR 2824); Medicare Commission
Doctor-Patient Relationship and Research Protection Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
"The Affordable Health Choices Act" (HR 3200, S xxx); "The America's Health Future Act" (S xxx); Waxman medicare Part-D rebate; Comparative effectiveness research (HR 2502, HR 2824); Comparative effectiveness research; Sunshine Amendments
America's Affordable Health Choices Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
America's Affordable Health Choices Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
"The Affordable Health Choices Act" (HR 3200, S xxx); "The America's Health Future Act" (S xxx); Waxman medicare Part-D rebate; Comparative effectiveness research (HR 2502, HR 2824); Comparative effectiveness research; Sunshine Amendments
America's Affordable Health Choices Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Health care reform; Follow-on biologics; "The Affordable Health Choices Act" (HR 3200, S xxx); "The America's Health Future Act" (S xxx); Importation; 340B
340B Program Improvement and Integrity Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicaid Rebate Increase, Medicaid rebate applied to Medicaid Managed Care Plans, Medicaid rebate applied to Part D, 340B Expansion (HR 444), Transparency
American Recovery and Reinvestment Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
American Recovery and Reinvestment Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Off-shore tax (HR 1265), Repatriation (HR 1), American Recovery and Reinvestment Act (S 1)
Patient-Centered Outcomes Research Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Health Care Reform, Comparative Effectiveness Research (S 1213, HR 2502, S 1259), Drug Importation, Follow-on biologics (HR 1548, HR 1427, S 726)
Health Care Reform, Comparative Effectiveness Research (S 1213, HR 2502, S 1259), Drug Importation, Follow-on biologics (HR 1548, HR 1427, S 726)
A bill to authorize the award of a Congressional gold medal to the Montford Point Marines of World War II.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
America's Healthy Future Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Physician Payments Sunshine Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Follow-on biologics (HR 1548, HR 1427, S 726), Patent Reform (HR 1260, S 515, S 615), China IPR, Thailand IPR, Global Intellectual Property Rights and Anti-Counterfeiting
A bill to provide additional personnel authorities for the Special Inspector General for Afghanistan Reconstruction.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Follow-on biologics (HR 1548, HR 1427, S 726), Patent Reform (HR 1260, S 515, S 615), China IPR, Thailand IPR, Global Intellectual Property Rights and Anti-Counterfeiting
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Follow-on biologics (HR 1548, HR 1427, S 726), Patent Reform (HR 1260, S 515, S 615), China IPR, Thailand IPR, Global Intellectual Property Rights and Anti-Counterfeiting
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Health Care Reform, Comparative Effectiveness Research (S 1213, HR 2502, S 1259), Drug Importation, Follow-on biologics (HR 1548, HR 1427, S 726)
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Physician Pathology Services Continuity Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
American Middle Class Tax (AMT) Relief Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Comparative Effectiveness (S 3408); Food & Drug Safety (HR 3610); Biosimilars (HR 5629, HR 1956, HR 1038, S 1695); Transparency (S 2029, HR 5605); Healthcare Reform (Belgium, Germany, Italy, United Kingdom, South Africa); MDR-TB
Patient Protection and Innovative Biologic Medicines Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Comparative Effectiveness (S 3408); Food & Drug Safety (HR 3610); Biosimilars (HR 5629, HR 1956, HR 1038, S 1695); Transparency (S 2029, HR 5605); Healthcare Reform (Belgium, Germany, Italy, United Kingdom, South Africa); MDR-TB
Food and Drug Import Safety Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Comparative Effectiveness (S 3408); Food & Drug Safety (HR 3610); Biosimilars (HR 5629, HR 1956, HR 1038, S 1695); Transparency (S 2029, HR 5605); Healthcare Reform (Belgium, Germany, Italy, United Kingdom, South Africa); MDR-TB
Physician Payments Sunshine Act of 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Comparative Effectiveness (S 3408); Food & Drug Safety (HR 3610); Biosimilars (HR 5629, HR 1956, HR 1038, S 1695); Transparency (S 2029, HR 5605); Healthcare Reform (Belgium, Germany, Italy, United Kingdom, South Africa); MDR-TB
Comparative Effectiveness (S 3408); Food & Drug Safety (HR 3610); Biosimilars (HR 5629, HR 1956, HR 1038, S 1695); Transparency (S 2029, HR 5605); Healthcare Reform (Belgium, Germany, Italy, United Kingdom, South Africa); MDR-TB
Biologics Price Competition and Innovation Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Comparative Effectiveness (S 3408); Food & Drug Safety (HR 3610); Biosimilars (HR 5629, HR 1956, HR 1038, S 1695); Transparency (S 2029, HR 5605); Healthcare Reform (Belgium, Germany, Italy, United Kingdom, South Africa); MDR-TB
Physician Payments Sunshine Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Comparative Effectiveness (S 3408); Food & Drug Safety (HR 3610); Biosimilars (HR 5629, HR 1956, HR 1038, S 1695); Transparency (S 2029, HR 5605); Healthcare Reform (Belgium, Germany, Italy, United Kingdom, South Africa); MDR-TB
Comparative Effectiveness Research Act of 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Comparative Effectiveness (S 3408); Food & Drug Safety (HR 3610); Biosimilars (HR 5629, HR 1956, HR 1038, S 1695); Transparency (S 2029, HR 5605); Healthcare Reform (Belgium, Germany, Italy, United Kingdom, South Africa); MDR-TB
Stop Tuberculosis (TB) Now Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Uninsured (S 1019), D-ATLAS, Tri-Care (S 1547 & HR 1585), MDR-TB (S 968 & HR 1567), Health Care Reform
Stop Tuberculosis (TB) Now Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Health Care Reform Uninsured (S 1019) Stop Tuberculosis Now (S 968 & HR 1567) MDR-TB
Intellectual Property, Patent Reform (S 3818 & HR 1908), Follow-on Biologics (S 1695), Compulsory Licensing, Counterfeiting
Patent Reform (S 1145 & HR 1908) Intellectual Property Rights Enforcement (S 522) Compulsory Licensing (Thailand) Product Patent Issues (Norway & Spain) Regulatory & IP Reform (Japan, Korea, China, Taiwan, India, Thailand, Philippines, Russia, Turkey, Poland, Czech Republic, Mexico)
Patient Protection and Innovative Biologic Medicines Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Follow-on Biologics (HR 1956)
Social Security Card Fortification Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation (S 1644, HR 2368, HR 2900, HR 3161) Anti-counterfeiting Free Trade Agreements
Food and Drug Administration Amendments Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation (S 1644, HR 2368, HR 2900, HR 3161) Anti-counterfeiting Free Trade Agreements
Food and Drug Administration Amendments Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation (S 1644 & HR 2638 & HR 2900), Anti-counterfeiting, Free Trade Agreement
Food and Drug Administration Amendments Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Prescription Drug User Fee Act (S 1082 & HR 2900)
Food and Drug Administration Amendments Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
PDUFA (S 1082 & HR 2900) Prescription Drug User Fee Act Counterfeiting (S 242, HR 380)
Pharmaceutical Market Access and Drug Safety Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
PDUFA (S 1082 & HR 2900) Prescription Drug User Fee Act Counterfeiting (S 242, HR 380)
Medicare Prescription Drug Price Negotiation Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare (S 250 & HR 4), SCHIP
Medicare Prescription Drug Price Negotiation Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
SCHIP (HR 3162) Medicare (S 250 & HR 4) Average Manufacturer Proce (S 1951)
Universal Health Care Choice and Access Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Health Care Reform Uninsured (S 1019) Stop Tuberculosis Now (S 968 & HR 1567) MDR-TB
Universal Health Care Choice and Access Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Uninsured (S 1019), D-ATLAS, Tri-Care (S 1547 & HR 1585), MDR-TB (S 968 & HR 1567), Health Care Reform
Patent Reform (S 1145 & HR 1908) Intellectual Property Rights Enforcement (S 522) Compulsory Licensing (Thailand) Product Patent Issues (Norway & Spain) Regulatory & IP Reform (Japan, Korea, China, Taiwan, India, Thailand, Philippines, Russia, Turkey, Poland, Czech Republic, Mexico)
Department of Homeland Security Appropriations Act, 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation (S 1644 & HR 2638 & HR 2900), Anti-counterfeiting, Free Trade Agreement
Department of Homeland Security Appropriations Act, 2008
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation (S 1644, HR 2368, HR 2900, HR 3161) Anti-counterfeiting Free Trade Agreements
Biologics Price Competition and Innovation Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Follow-on Biologics (S 1695)
Biologics Price Competition and Innovation Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual Property, Patent Reform (S 3818 & HR 1908), Follow-on Biologics (S 1695), Compulsory Licensing, Counterfeiting
Fair Medicaid Drug Payment Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
SCHIP (HR 3162) Medicare (S 250 & HR 4) Average Manufacturer Proce (S 1951)
Pharmaceutical Market Access and Drug Safety Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
PDUFA (S 1082 & HR 2900) Prescription Drug User Fee Act Counterfeiting (S 242, HR 380)
Medicare Enhancements for Needed Drugs Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare (S 250 & HR 4), SCHIP
Medicare Enhancements for Needed Drugs Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
SCHIP (HR 3162) Medicare (S 250 & HR 4) Average Manufacturer Proce (S 1951)
Intellectual Property Rights Enforcement Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patent Reform (S 1145 & HR 1908) Intellectual Property Rights Enforcement (S 522) Compulsory Licensing (Thailand) Product Patent Issues (Norway & Spain) Regulatory & IP Reform (Japan, Korea, China, Taiwan, India, Thailand, Philippines, Russia, Turkey, Poland, Czech Republic, Mexico)
Stop Tuberculosis (TB) Now Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Uninsured (S 1019), D-ATLAS, Tri-Care (S 1547 & HR 1585), MDR-TB (S 968 & HR 1567), Health Care Reform
Stop Tuberculosis (TB) Now Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Health Care Reform Uninsured (S 1019) Stop Tuberculosis Now (S 968 & HR 1567) MDR-TB
Intellectual Property, Patent Reform (S 3818 & HR 1908), Follow-on Biologics (S 1695), Compulsory Licensing, Counterfeiting
To establish an office to oversee research compliance and assurance within the Veterans Health Administration of the Department of Veterans Affairs.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Uninsured (S 1019), D-ATLAS, Tri-Care (S 1547 & HR 1585), MDR-TB (S 968 & HR 1567), Health Care Reform
Small Business Expensing Permanency Act of 2003
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation (S 1644 & HR 2638 & HR 2900), Anti-counterfeiting, Free Trade Agreement
To ratify the authority of the Federal Trade Commission to establish a do-not-call registry.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation (S 1644, HR 2368, HR 2900, HR 3161) Anti-counterfeiting Free Trade Agreements
To require cigarette products to be placed under or behind the counter in retail sales.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
SCHIP (HR 3162) Medicare (S 250 & HR 4) Average Manufacturer Proce (S 1951)
Intellectual Property Patent Reform (S3818)
PFUFA V; Patient Protection and Affordable Care Act;
Bipartisian Tax Fairness and Simplification Act (S727)
America Invents Act (patent reform)(HR 1249); Anti-Counterfeiting; Patient safety
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2011 · first_quarter · Q1
340 B Legislation, PDUFA V, Importation, Patient Protection and Affordable Care Act
Medicare Part D Non-Interference, Rebate Issues, Medicare Decisions Accountability Act of 2011 - IPAB Repeal (HR 452)
Corporate Tax Reform, Patent Reform (S 23, HR 1249)
The America Invents Act of 2011 (HR 1249), BiPartisan Tax Fairness and Simplifiation Act (S 727)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2010 · second_quarter · Q2
Financial derivatives (HR 4173)
Patent Reform Ace (S 515); Russian data exclusitivity; Saudi Zyprexa Patent nullification; Russia DE Enactment, Manager's Amendment to S 515; Counterfeit medicines
Healthcare Reform (HR 4872 & HR 3590); FOB provisions (HR 3200)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2010 · first_quarter · Q1
Medicare reimbursement and coverage policies; Healthcare reform (HR 3590 & HR 4872); food safety; Patient Protection and Affordable Care Act (HR 3590); FOB provisions (HR 3200)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2009 · fourth_quarter · Q4
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Waxman Medicare part-D Non-Interference; Comparative Effectiveness Research (HR 2502, HR 2824); Medicare Commission
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2009 · third_quarter · Q3
Patent legislation; HR 1548; Follow-On Biologics; Russia IP; A;geria market access; Brazil IP; Mexico IP; Argentina IP; Chile IP; Columbia IP; Peru IP; Isreal IP; Saudi Arbia pricing and IP; Turkey pricing
Health care reform; Follow-on biologics; "The Affordable Health Choices Act" (HR 3200, S xxx); "The America's Health Future Act" (S xxx); Importation; 340B
"The Affordable Health Choices Act" (HR 3200, S xxx); "The America's Health Future Act" (S xxx); Waxman medicare Part-D rebate; Comparative effectiveness research (HR 2502, HR 2824); Comparative effectiveness research; Sunshine Amendments
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2009 · second_quarter · Q2
Follow-on biologics (HR 1548, HR 1427, S 726), Patent Reform (HR 1260, S 515, S 615), China IPR, Thailand IPR, Global Intellectual Property Rights and Anti-Counterfeiting
Health Care Reform, Comparative Effectiveness Research (S 1213, HR 2502, S 1259), Drug Importation, Follow-on biologics (HR 1548, HR 1427, S 726)
Tax deferral
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2009 · first_quarter · Q1
Medicaid Rebate Increase, Medicaid rebate applied to Medicaid Managed Care Plans, Medicaid rebate applied to Part D, 340B Expansion (HR 444), Transparency
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · fourth_quarter · Q4
Medicare, Medicaid
Comparative Effectiveness (S 3408); Food & Drug Safety (HR 3610); Biosimilars (HR 5629, HR 1956, HR 1038, S 1695); Transparency (S 2029, HR 5605); Healthcare Reform (Belgium, Germany, Italy, United Kingdom, South Africa); MDR-TB
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · third_quarter · Q3
Waxman Medicare Part D non-interference,
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2007 · year_end · YY
Importation (S 1644, HR 2368, HR 2900, HR 3161) Anti-counterfeiting Free Trade Agreements
PDUFA (S 1082 & HR 2900) Prescription Drug User Fee Act Counterfeiting (S 242, HR 380)
SCHIP (HR 3162) Medicare (S 250 & HR 4) Average Manufacturer Proce (S 1951)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2007 · mid_year · MM
Importation (S 1644 & HR 2638 & HR 2900), Anti-counterfeiting, Free Trade Agreement
Intellectual Property, Patent Reform (S 3818 & HR 1908), Follow-on Biologics (S 1695), Compulsory Licensing, Counterfeiting
Medicare (S 250 & HR 4), SCHIP
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2006 · year_end · YY
Health Care Reform Pricing Issues Importation
Intellectual Property Patent Reform (S3818)
International Trade Issues -- Peru FTA, Poland Price Cut, Germany Jumbo Groups, Japan Pricing & Regulatory Reform, Korea FTA, Russia WTO
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2006 · mid_year · MM
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), Natl Economic Council (NEC), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Off-shore tax (HR 1265), Repatriation (HR 1), American Recovery and Reinvestment Act (S 1)
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Security Agency (NSA), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Patent Reform (S 1145 & HR 1908) Intellectual Property Rights Enforcement (S 522) Compulsory Licensing (Thailand) Product Patent Issues (Norway & Spain) Regulatory & IP Reform (Japan, Korea, China, Taiwan, India, Thailand, Philippines, Russia, Turkey, Poland, Czech Republic, Mexico)
Follow-on Biologics (HR 1956)
Direct to Consumer Advertising
Health Care Reform Uninsured (S 1019) Stop Tuberculosis Now (S 968 & HR 1567) MDR-TB
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Follow-on Biologics (S 1695)
Prescription Drug User Fee Act (S 1082 & HR 2900)
Uninsured (S 1019), D-ATLAS, Tri-Care (S 1547 & HR 1585), MDR-TB (S 968 & HR 1567), Health Care Reform
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Health Technology
Medicare implementation Non-interference MMA & Patient Assistance Programs Mental Health Access
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)